Pd01-09 a Prospective Cohort Study Comparing the Efficacy of Neoadjuvant Abitrexone+/- Docetaxel and Radical Prostatectomy in Locally Advanced Prostate Cancer

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) I (PD01)1 May 2024PD01-09 A PROSPECTIVE COHORT STUDY COMPARING THE EFFICACY OF NEOADJUVANT ABITREXONE+/- DOCETAXEL AND RADICAL PROSTATECTOMY IN LOCALLY ADVANCED PROSTATE CANCER Xuan Wang, Zheng tong Lv, Wei Zhang, Jian ye Wang, and Ming Liu Xuan WangXuan Wang , Zheng tong LvZheng tong Lv , Wei ZhangWei Zhang , Jian ye WangJian ye Wang , and Ming LiuMing Liu View All Author Informationhttps://doi.org/10.1097/01.JU.0001009540.33579.43.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To compare the efficacy and safety of neoadjuvant abitrexone+/- docetaxel and radical prostatectomy in the treatment of locally advanced prostate cancer. METHODS: Prospective enroll patients who were diagnosed with prostate adenocarcinoma by prostate biopsy, with clinical staging of cT3a-cT4N0M0 or any cT, N1M0, age ≤78 years old, ECOG score ≤1, willing to undergo radical prostatectomy, and could tolerate neoadjuvant therapy and surgery. . This is a non-randomized, non-blinded, prospective cohort study. Study group received 6-month neoadjuvant LHRH-α+ abitrexone+prednisone. PSA and MRI were rechecked at 3 months, and if PSA did not decrease to ≤0.1 ng/ml and the clinical stage under MRI did not decrease to within T2 stage, 3-course docetaxel chemotherapy should be added. After 6 months of neoadjuvant treatment, radical prostatectomy was performed. Control group received radical prostatectomy directly. The effectiveness and safety of two arms were compared. RESULTS: 30 patients in study group and 33 patients in control group were enrolled, and the initial PSA was 26.90±21.26 ng/ml and 22.56±20.01 ng/ml, respectively (p=0.408). There were no significant differences in other preoperative characteristics between the two groups, such as age, PI-RADS v2 score, clinical ISUP grade and clinical T stage. All patients successfully completed radical prostatectomy, and no complications of Clavien-Dindo grade 2 or above occurred during perioperative period. Postoperative pathology showed that pCR was achieved in 4 patients in study group, and the maximum diameter of the lesions in two groups was 0.92±0.95 cm and 2.84±0.97cm, respectively (p<0.001). The positive surgical margin rates in study group and control group were 13.3% and 54.5%, respectively (p<0.001). The rates of persistent PSA status in two groups were 4.8% and 40% (p=0.004), and the rates of postoperative adjuvant therapy were 13.6% and 51.9% (p=0.005), respectively. The continence recovery rates were 81.8% and 51.5%, respectively (p=0.022). CONCLUSIONS: For patients with locally advanced prostate cancer, neoadjuvant abitrexone+/- docetaxel can effectively reduce the positive surgical margin rates, the proportion of postoperative adjuvant treatment compared to radical prostatectomy. Further follow-up is needed for biochemical recurrence free survival and overall survival. Source of Funding: National High Level Hospital Clinical Research Funding: BJ-2020-171, BJ-2022-158 © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e66 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Xuan Wang More articles by this author Zheng tong Lv More articles by this author Wei Zhang More articles by this author Jian ye Wang More articles by this author Ming Liu More articles by this author Expand All Advertisement PDF downloadLoading ...